Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01534715 · ClinicalTrials.gov registry record · Phase 1
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, sponsored by ImmunoGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 7
- Study locations
NCT01534715: Completed Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, sponsored by ImmunoGen.
NCT01534715 is a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin that has completed, run by ImmunoGen. The registered enrollment target is 49 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01534715, a Phase 1 study of Chronic Lymphocytic Leukemia and Lymphoma, Non-Hodgkin, has completed, sponsored by ImmunoGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Conditions Studied
Interventions
- DRUG IMGN529
Study Locations (7)
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Ohio
- Ohio State University - Columbus
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- CTRC at UTHSCSA - San Antonio
Wisconsin
- Medical College of Wisconsin - Milwaukee
Other
- Oncology Institute of Southern Switzerland - Bellinzona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
What the finished NCT01534715 record still lists
NCT01534715 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which IMGN529 is the first listed.
NCT01534715 lists 7 locations in 7 states (Massachusetts, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT01534715 about?
NCT01534715 is a clinical study titled "IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia". The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
What is the current status of trial NCT01534715?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-01. Estimated completion is 2016-07.
What conditions does trial NCT01534715 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT01534715?
The interventions under investigation include: IMGN529 (DRUG).
Who is sponsoring clinical trial NCT01534715?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01534715 being conducted?
This trial has 7 study locations across Massachusetts, New York, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01534715's enrollment target sits among peer trials
49 106th of 187 higher than 80 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia